Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use

Fig. 3

Comparison of the vulnerability to VDPV virus after OPV cessation by serotype. Selected percentiles from the distribution of Rn values for VDPV virus (stage 19) among 520 subpopulations that used OPV-only in 2013 in the global model [4] as a function of time after homotypic OPV cessation (analysis I). These base case results assume tOPV intensification before the tOPV-bOPV switch for serotype 2 (adopted from Duintjer Tebbens et al. 2016 [15]) and the assume continued high maintenance of population immunity with bOPV SIAs until bOPV cessation for serotypes 1 and 3. a Serotype 1. b Serotype 2. c Serotype 3

Back to article page